AJANTPHARM2023-10-012023-12-31 AJANTPHARM2023-10-012023-12-31 AJANTPHARM2023-10-012023-12-31in-bse-fin:OneOperatingExpenses01Member AJANTPHARM2023-10-012023-12-31in-bse-fin:FourOperatingExpenses01Member AJANTPHARM2023-12-31 AJANTPHARM2023-10-012023-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member AJANTPHARM2023-10-012023-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member AJANTPHARM2023-10-012023-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member AJANTPHARM2023-10-012023-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532331 AJANTPHARM NOTLISTED Ajanta Pharma Limited Equity 2023-04-01 2024-03-31 2024-01-31 2024-01-19 INR Crores Third quarter 14:00:00 15:45:00 2024-01-31 2024-01-31 Not applicable Single segment Pharmaceutical 2023-10-01 2023-12-31 Unaudited Consolidated 11051500000.00 135900000.00 11187400000.00 2390500000.00 392900000.00 158300000.00 2313500000.00 24900000.00 342600000.00 2655600000.00 8278300000.00 2909100000.00 0.00 2909100000.00 913100000.00 -104300000.00 808800000.00 0.00 2100300000.00 0.00 0.00 0.00 0.00 2100300000.00 27600000.00 2127900000.00 0.00 0.00 0.00 0.00 252700000.00 2 16.68 16.67 0.00 0.00 16.68 16.67 1. The above consolidated unaudited financial results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 31 January 2024. The statutory auditors have expressed unmodified opinion on the results for the quarter and nine month period ended 31 December 2023. The review report has been filed with the stock exchange and is available on company website. 2. The consolidated unaudited financial results of the Company and its wholly owned subsidiaries (“the Group”) have been prepared as per Ind AS 110 on Consolidated Financial Statements. There is no minority interest. 3. Board of Directors have approved 2nd interim dividend of Rs. 327 Crore for financial year 2023-24 to its shareholders @ Rs. 26 per share on the face value of Rs. 2 per share. 4. Other income / Other expense includes : Quarter ended Nine months ended Year ended Rs. in Crore 31-Dec-23 30-Sep-23 31-Dec-22 31-Dec-23 31-Dec-22 31-Mar-23 Foreign exchange gain (in other income) 4.11 12.81 27.21 19.03 87.78 66.07 Foreign exchange loss (in other expense) 7.58 - 36.99 - 43.34 18.82 5. During nine month ended 31 December 2023, 1,000 (previous year 1,000) equity shares of Rs. 2 each, fully paid up, were allotted upon exercise of vested options pursuant to the Share Based Incentive Plan, 2019, resulting in an increase in the paid-up share capital by Rs. 2,000 (previous year Rs. 2,000) and securities premium by Rs. 0.18 crores (previous year Rs. 0.18 crores). 6. On 10 March 2023, Company has announced buy back of its 22,10,500 equity shares, being 2.59% of the total paid up equity share capital at Rs. 1,425 per equity share for an aggregate amount of Rs. 315.00 crores. The buy back opened on 31 March 2023, closed on 10 April 2023 and Company extinguished those shares on 19 April 2023. 7. The Group operates exclusively in one reportable business segment i.e., Pharmaceuticals . 8. The Financial Results are available for investors on the company's website www.ajantapharma.com and stock exchange websites www.nseindia.com and www.bseindia.com. Single segment 2023-04-01 2023-12-31 Unaudited Consolidated 31546300000.00 491000000.00 32037300000.00 6804000000.00 1259100000.00 -41200000.00 6668300000.00 56800000.00 1011500000.00 7919900000.00 23678400000.00 8358900000.00 0.00 8358900000.00 2489500000.00 -265100000.00 2224400000.00 0.00 6134500000.00 0.00 0.00 0.00 0.00 6134500000.00 72000000.00 6206500000.00 0.00 0.00 0.00 0.00 252700000.00 2 48.72 48.68 0.00 0.00 48.72 48.68 Other Expenses 2655600000.00 Other Expenses 7919900000.00 Items that will not to be reclassified subsequently to profit or loss -8600000.00 Items that will not to be reclassified subsequently to profit or loss -24400000.00 -8600000.00 -24400000.00 -3000000.00 -8500000.00 Items that will be reclassified subsequently to profit or loss 33200000.00 Items that will be reclassified subsequently to profit or loss 87900000.00 33200000.00 87900000.00 0.00 0.00